Advanced Practice Providers

Adverse Event Management

Brain Cancer

Breast Cancer

Childhood/AYA Cancer

Disparities in cancer care

Drug Safety

Gastrointestinal Cancer

Genetics

Genitourinary Cancer

Gynecologic Cancers

Head and Neck Cancers

Hematology

Immuno-Oncology

Lung Cancer

Nurse Navigation

Prevention

Radiation Oncology

Sarcomas

Skin Cancer/Melanoma

Supportive Care

Survivorship

In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.

Lenvatinib Plus Pembrolizumab Elicits Durable Responses in Patients With Endometrial Cancer

Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer. 

Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer. 

GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies 

News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

Webinars

Subscribe

Partners

Articles

The FDA has granted full approval to pembrolizumab (Keytruda) for certain adult and pediatric patients with advanced MSI-H or dMMR solid tumors.

Pembrolizumab Receives Full FDA Approval for Treatment of Select Patients With dMMR/MSI-H Solid Tumors

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Hematologists have developed a framework of the core symptoms caregivers should look out for when caring for a patient who has just received CAR T-cell therapy. 

Core Framework Identifies Early Onset of CAR T-Cell Therapy Symptoms at Home

Major findings demonstrated that patients with colorectal cancer experienced generally low symptom severity with most symptoms remaining stable or improving following treatment.

Symptom Burden Analysis Supports Ongoing Posttreatment Analysis for Patients With CRC 

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

LinkedIn

Specialty

Clinical

Gynecologic Cancer

Sap Partners

1rem

Strategic Alliance Partners

Patients with clear cell renal cell carcinoma experienced reduced levels of hypoxia inducible factor-2 alpha expression following treatment with ARO-HIF2. 

Investigational RNA Interference Therapy, ARO-HIF2, Yields Encouraging Phase 1 Results in Clear Cell RCC

UT Southwestern Harold C. Simmons Comprehensive Cancer Center 

UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Latest Conference Coverage